Imagion Biosystems (ASX:IBX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Imagion Biosystems (ASX:IBX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Appendix 4C and Quarterly Activities Report - September 2026
IBX Secures Central Ethics Approval - Key Phase 2 Milestone
Imagion clears central ethics hurdle for MagSense HER2 Phase 1b/2 trial
MagSense Nanoparticle Manufacturing Update
Imagion resumes MagSense nanoparticle manufacturing through nanoComposix partnership
IBX Investor Presentation
Cleansing Notice
Application for quotation of securities - IBX
Application for quotation of securities - IBX
Notification of cessation of securities - IBX
IBX Phase 2 Clinical Trial Update
Imagion Biosystems Advances Phase 1b/2 Trial for MagSense® HER2 Imaging Agent with CRO Agreements and Product Ready for Distribution
Change of Director's Interest Notices - RP, BM, NW
Appendix 4D and Half-yearly Financial Report
Cleansing Notice
Application for quotation of securities - IBX
Cleansing Notice
Application for quotation of securities - IBX
Results of General Meeting
Appendix 4C and Quarterly Activities Report - June 2026
Proposed issue of securities - IBX
Non-Dilutive Short-Term Funding Secured